The last 80 years in primary immunodeficiency: How far have we come, how far need we go?

Journal of Allergy and Clinical Immunology

Volumn 117, Issue 4, 2006, Pages 748-752

  Shearer, William T ^a   Fischer, Alain ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

bone marrow stem cell transplantation; gene therapy; history and future prospects; intravenous immunoglobulin treatment; molecular defects; Primary immunodeficiency

Indexed keywords

ANTIRETROVIRUS AGENT; IMMUNOGLOBULIN; WISKOTT ALDRICH SYNDROME PROTEIN;

ATAXIA TELANGIECTASIA; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; COMBINED IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; DENDRITIC CELL; DNA REPAIR; EDITORIAL; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; INNATE IMMUNITY; NEUTROPHIL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; WISKOTT ALDRICH SYNDROME; X CHROMOSOME LINKED DISORDER;

EID: 33646049323     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2006.02.029     Document Type: Editorial

References (67)

1. Syllaba L., and Henner K. Contribution a l'independance de l'athetose double idiopathique et congenitale: atteinte familiale, syndrome dystrophique, signe du reseau vasculaire conjonctival, integrite psychique. Rev Neurol (Paris) 1 (1926) 541-562
2. Stiehm E.R., and Johnston Jr. R.B. A history of pediatric immunology. Pediatr Res 57 (2005) 458-467
3. Puck J.N., and Malech H.L. Gene therapy for immune disorders: good news tempered by bad news. J Allergy Clin Immunol 117 (2006) 865-869
4. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., et al. Use of intravenous immunoglobulin in human disease. J Allergy Clin Immunol 117 (2006) S525-S554
5. Buckley R.H. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 22 (2004) 625-655
6. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288 (2000) 669-672
7. Gaspar H.B., Parsley K.L., Howe S., King D., Gilmour K.C., Sinclair J., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364 (2004) 2181-2187
8. Aiuti A., Slavin S., Aker M., Ficara F., Deola S., Mortellaro A., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296 (2002) 2410-2413
9. Wen L., Atkinson J.P., and Giclas P.C. Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol 113 (2004) 585-593
10. Chinen J., and Puck J.M. Successes and risks of gene therapy in primary immunodeficiencies. J Allergy Clin Immunol 113 (2004) 595-603
11. Rosenzweig S.D., and Holland S.M. Phagocyte immunodeficiencies and their infections. J Allergy Clin Immunol 113 (2004) 620-626
12. Dworetzky M, Cohen S. Pioneers and milestones. Robert A. Good, MD, PhD, DSc. J Allergy Clin Immunol 2004;113:793-800.
13. Hamilton R.G., and Franklin Adkinson Jr. N. In vitro assays for the diagnosis of IgE-mediated disorders. J Allergy Clin Immunol 114 (2004) 213-225
14. Fleisher T.A., and Oliveira J.B. Functional and molecular evaluation of lymphocytes. J Allergy Clin Immunol 114 (2004) 227-234
15. Tosi M.F. Innate immune responses to infection. J Allergy Clin Immunol 116 (2005) 241-249
16. Thorley-Lawson D.A. EBV the prototypical human tumor virus-just how bad is it?. J Allergy Clin Immunol 116 (2005) 251-261
17. Mehandru S., Tenner-Racz K., Racz P., and Markowitz M. The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection. J Allergy Clin Immunol 116 (2005) 419-422
18. Casanova J.L., Fieschi C., Bustamante J., Reichenbach J., Remus N., von Bernuth H., et al. From idiopathic infectious diseases to novel primary immunodeficiencies. J Allergy Clin Immunol 116 (2005) 426-430
19. Liossis S.N., and Tsokos G.C. Monoclonal antibodies and fusion proteins in medicine. J Allergy Clin Immunol 116 (2005) 721-729
20. Presta L.G. Selection, design, and engineering of therapeutic antibodies. J Allergy Clin Immunol 116 (2005) 731-736
21. Lee S.J., and Kavanaugh A. Adverse reactions to biologic agents: focus on autoimmune disease therapies. J Allergy Clin Immunol 116 (2005) 900-905
22. Kroczek R., and Hamelmann E. T-cell costimulatory molecules: optimal targets for the treatment of allergic airway disease with monoclonal antibodies. J Allergy Clin Immunol 116 (2005) 906-909
23. Geha R.S., and Charles A. Janeway and Fred S. Rosen: the discovery of gamma globulin therapy and primary immunodeficiency diseases at Boston Children's Hospital. J Allergy Clin Immunol 116 (2005) 937-940
24. Mazer B.D., Al-Tamemi S., Yu J.W., and Hamid Q. Immune supplementation and immune modulation with intravenous immunoglobulin. J Allergy Clin Immunol 116 (2005) 941-944
25. Chatila T.A. Role of regulatory T cells in human diseases. J Allergy Clin Immunol 116 (2005) 949-959
26. Akdis M., Blaser K., and Akdis C.A. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 116 (2005) 961-968
27. Seroogy C.M., and Gern J.E. The role of T regulatory cells in asthma. J Allergy Clin Immunol 116 (2005) 996-999
28. Goleva E., Cardona I.D., Ou L.S., and Leung D.Y. Factors that regulate naturally occurring T regulatory cell-mediated suppression. J Allergy Clin Immunol 116 (2005) 1094-1100
29. Cohen S. Jacques Miller on the thymus. J Allergy Clin Immunol 116 (2005) 1170-1171
30. Cohen S.G. How the immunologic function of the thymus was discovered. J Allergy Clin Immunol 116 (2005) 1171-1174
31. Ochs M., and Thrasher A.J. Wiskott-Aldrich syndrome. J Allergy Clin Immunol 117 (2006) 725-738
32. Snapper S.B., Meelu P., Nguyen D., Stockton B.M., Bozza P., Alt F.W., et al. WASP deficiency leads to global defects of directed leukocyte migration in vitro and in vivo. J Leukoc Biol 77 (2005) 993-998
33. de Noronha S., Hardy S., Sinclair J., Blundell M.P., Strid J., Schulz O., et al. Impaired dendritic-cell homing in vivo in the absence of Wiskott-Aldrich syndrome protein. Blood 105 (2005) 1590-1597
34. Gallego MD, de la Fuente MA, Anton IM, Snapper S, Fuhlbrigge R, Geha RS. WIP and WASP play complementary roles in T cell homing and chemotaxis to SDF-1α. Int Immunol. In press 2006.
35. Westerberg L., Larsson M., Hardy S.J., Fernandez C., Thrasher A.J., and Severinson E. Wiskott-Aldrich syndrome protein deficiency leads to reduced B-cell adhesion, migration, and homing, and a delayed humoral immune response. Blood 105 (2005) 1144-1152
36. Charrier S., Stockholm D., Seye K., Opolon P., Taveau M., Gross D.A., et al. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther 12 (2005) 597-606
37. Hacein-Bey-Abina S., Le Deist F., Carlier F., Bouneaud C., Hue C., De Villartay J.P., et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346 (2002) 1185-1193
38. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
39. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., McIntyre E., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348 (2003) 255-256
40. Emery D.W., Yannaki E., Tubb J., and Stamatoyannopoulos G. A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci U S A 97 (2000) 9150-9155
41. Urnov F.D., Miller J.C., Lee Y.L., Beausejour C.M., Rock J.M., Augustus S., et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435 (2005) 646-651
42. Castigli E., and Geha R.S. Molecular basis of common variable immunodeficiency (CVID). J Allergy Clin Immunol 117 (2006) 740-746
43. Castigli E., Wilson S.A., Scott S., Dedeoglu F., Xu S., Lam K.P., et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 201 (2005) 35-39
44. Litinskiy M.B., Nardelli B., Hilbert D.M., He B., Schaffer A., Casali P., et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3 (2002) 822-829
45. Castigli E., Wilson S.A., Garibyan L., Rachid R., Bonilla F., Schneider L., et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 37 (2005) 829-834
46. Salzer U., Chapel H.M., Webster A.D., Pan-Hammarstrom Q., Schmitt-Graeff A., Schlesier M., et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 37 (2005) 820-828
47. Cunningham-Rundles C., and Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 92 (1999) 34-48
48. Grimbacher B., Hutloff A., Schlesier M., Glocker E., Warnatz K., Drager R., et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 4 (2003) 261-268
49. Berglund L.J., Jones G.J., Murali R., and Fulcher D.A. TACI mutation with invasive polyclonal CD8+ T-cell lymphoproliferation in a patient with common variable immunodeficiency. J Allergy Clin Immunol 117 (2006) 870-877
50. Lin J., Stiehm E.R., Liebhaber M., Roberts R.L., and Dyer Z. Use of etanercept for treatment of cutaneous granuloma in common variable immunodeficiency. J Allergy Clin Immunol 117 (2006) 878-882
51. Roifman C.M., Gu Y., and Cohen A. Mutations in the RNA component of RNase MRP may cause Omenn syndrome. J Allergy Clin Immunol 117 (2006) 897-903
52. Villa A., Santagata S., Bozzi F., Giliani S., Frattini A., Imberti L., et al. Partial V(D)J recombination activity leads to Omenn syndrome. Cell 93 (1998) 885-896
53. Villa A., Sobacchi C., Notarangelo L.D., Bozzi F., Abinun M., Abrahamsen T.G., et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood 97 (2001) 81-88
54. Corneo B., Moshous D., Gungor T., Wulffraat N., Philippet P., Le Deist F.L., et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood 97 (2001) 2772-2776
55. Ege M., Ma Y., Manfras B., Kalwak K., Lu H., Lieber M.R., et al. Omenn syndrome due to ARTEMIS mutations. Blood 105 (2005) 4179-4186
56. Aleman K., Noordzij J.G., de Groot R., van Dongen J.J., and Hartwig N.G. Reviewing Omenn syndrome. Eur J Pediatr 160 (2001) 718-725
57. Ridanpaa M., van Eenennaam H., Pelin K., Chadwick R., Johnson C., Yuan B., et al. Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. Cell 104 (2001) 195-203
58. Schofer O., Blaha I., Mannhardt W., Zepp F., Stallmach T., and Spranger J. Omenn phenotype with short-limbed dwarfism. J Pediatr 118 (1991) 86-89
59. Saitoh A., Singh K., Sharsti S., Powell C.A., Fenton T., Fletcher C.V., et al. Maintenance of CD4+ T-lymphocyte counts in HIV-infected children is associated with new thymic emigrants before and during successful antiretroviral therapy. J Allergy Clin Immunol 117 (2006) 909-915
60. Gortmaker S.L., Hughes M., Cervia J., Brady M., Johnson G.M., Seage III G.R., et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 345 (2001) 1522-1528
61. Saitoh A., Hsia K., Fenton T., Powell C.A., Christopherson C., Fletcher C.V., et al. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J Infect Dis 185 (2002) 1409-1416
62. Antas P.R., Ding L., Hackman J., Reeves-Hammock L., Shintani A.K., Schiffer J., et al. Decreased CD4+ lymphocytes and innate immune responses in adults with prior extrapulmonary tuberculosis. J Allergy Clin Immunol 117 (2006) 916-923
63. Bonilla F.A., and Geha R.S. Are you immunodeficient?. J Allergy Clin Immunol 116 (2005) 423-425
64. Levi M., Choi G., Picavet C., and Hack E. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angio-edema due to C1-inhibitor deficiency. J Allergy Clin Immunol 117 (2006) 904-908
65. Buckley R.H. Primary immunodeficiency or not? Making the correct diagnosis. J Allergy Clin Immunol 117 (2006) 756-758
66. Notarangelo L., Casanova J.L., Conley M.E., Fischer A., Puck J.N., Roifman C.M., et al. Primary immunodeficiency diseases: an update. J Allergy Clin Immunol 117 (2006) 883-896
67. Kirkpatrick C., Dreskin S., Marrack P., and Henry N. Claman, MD: identification of cellular cooperation in antibody production. J Allergy Clin Immunol 117 (2006) 959-964